GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Current Deferred Revenue

Belite Bio (Belite Bio) Current Deferred Revenue : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Belite Bio's current deferred revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

Belite Bio Current Deferred Revenue Historical Data

The historical data trend for Belite Bio's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Current Deferred Revenue Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- - - -

Belite Bio Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Belite Bio Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Belite Bio's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Belite Bio (Belite Bio) Business Description

Traded in Other Exchanges
Address
12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.